Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05415527 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management

Study acronym: OPTIMOVA
StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Trial completed Show 5 more changesShow less
    • Primary completion date changed from estimate of Jun 10, 2027 to Apr 30, 2025
    • Study completion date changed from estimate of Jun 10, 2028 to Mar 18, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 4 words
  3. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jan 2027 to Jun 10, 2027
    • Study completion date: Jan 2028 to Jun 10, 2028
    • Site details revised
    v4
  4. Primary completion date: Jan 2024 to Jan 2027
    • Study completion date: Jan 2026 to Jan 2028
    v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Dec 2023 to Jan 2024
    • Study completion date: Dec 2025 to Jan 2026
    • Start date changed from estimate of Jun 10, 2022 to Jun 11, 2022
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Bergonié
40 trials monitored
See 1 trial at risk
Ovarian Cancer
1,336 trials monitored
See 90 trials at risk
Prospective, monocentric study evaluating the presence of sarcopenia prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management.
Trial Details
NCT Number NCT05415527
Lead Sponsor Institut Bergonié
Conditions
(from sponsor)		 Ovarian Carcinoma
Related terms Ovarian Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov